Design,delivery and efficacy testing of therapeutic nucleic acids used to inhibit hepatitis C virus gene expression in vitro and in vivo

Despite major achievements in the treatment ofchronic hepatitis C with the combination ofinterferons and the nucleoside analog ribavirin themajority of patients with chronic hepatitis C virus(HCV) infection cannot be treated effectively.Toimprove this response rate we used antisensetechnologies to inhibit HCV translation as possibleadditional option for experimental treatment.Antisense oligodeoxynucleotides(ODN) are

Therapeutic and Medicinal Uses of <i>Aloe vera</i>: A Review

The plant Aloe vera is used in Ayurvedic, Homoeopathic and Allopathic streams of medicine, and not only tribal community but also most of the people for food and medicine. The plant leaves contains numerous vitamins, minerals, enzymes, amino acids, natural sugars and other bioactive compounds with emollient, purgative, anti-microbial, anti inflammatory, antioxidant, aphrodisiac, anti-helmenthic, antifungal, antiseptic and cosmetic values for health care. This plant has potential to cure sunburns, burns and minor cuts, and even skin cancer. The external use in cosmetic primarily acts as skin healer and prevents injury of epithelial tissues, cures acne and gives a youthful glow to skin, also acts as extremely powerful laxative.

Continuous Wear of Hydrogel Contact Lenses for Therapeutic Use

Purpose: To investigate the efficacy and complications of continuous wear of etafilcon A for therapeutic use. Materials and Methods: The subjects were 228 eyes of 219 outpatients prescribed contact lens (CL) for one week of continuous therapeutic wear during 10 years. The reason for prescription of CLs, the primary disease, the duration of CL wear and the complications were assessed retrospectively. Results: The predominant reason for prescription of CLs was relief of pain or a foreign-body sensation (62.3%) and protection of the corneal epithelium (20.6%). The primary disease was post-penetrating keratoplasty (36.8%), followed by corneal epithelial erosion (14.5%), post-lamellar keratoplasty (14.0%) and bullous keratopathy (12.2%). The average duration of wearing single lens was 6.5 ± 3.2 days. The average duration of wearing CLs in total was 9.2 ± 10.7 months. The most frequent problem associated with continuous wear of CLs was their dropping out of CLs (12.3%). The complications associated with CLs included conjunctivitis with papillary hyperplasia, corneal erosion and superficial punctate keratitis, but corneal ulcer and corneal infiltrates were not found. Conclusion: Serious complications were not shown changing the lenses every week to keep to the prescribed time limit for continuous therapeutic wear, even if corneal epithelial barrier function is impaired.

Comparison of long-lasting therapeutic effects between succimer and penicillamine on hepatolenticular degeneration

ＩＮＴＲＯＤＵＣＴＩＯＮＨｅｐａｔｏｌｅｎｔｉｃｕｌａｒｄｅｇｅｎｅｒａｔｉｏｎ（ＨＬＤ）ｉｓａｎａｕｔｏｓｏｍａｌｒｅｃｅｓｉｖｅｄｉｓｏｒｄｅｒｔｈａｔｃａｕｓｅｓｃｈａｎｇｅｓｉｎｔｈｅｂａｓａｌｇａｎｇｌｉａａｎｄｌｉｖｅｒｔｈａｔｒｅｓｐｅ...

Functional dyspepsia of ulcer-dysmotility type:clinical incidence and therapeutic strategy

Ｆｕｎｃｔｉｏｎａｌｄｙｓｐｅｐｓｉａｏｆｕｌｃｅｒｄｙｓｍｏｔｉｌｉｔｙｔｙｐｅ：ｃｌｉｎｉｃａｌｉｎｃｉｄｅｎｃｅａｎｄｔｈｅｒａｐｅｕｔｉｃｓｔｒａｔｅｇｙＷＡＮＧＸｉａｏＺｈｏｎｇａｎｄＬＩＮＧｕＺｈｅｎＳｕｂｊｅｃｔｈｅａａｄｉｎｇｓ...

Therapeutic role of template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract

Lymphadenectomy for urothelial carcinoma of the upper urinary tract has attracted the attention of physicians. The mapping study of lymphatic spread has shown that a relatively wide area should comprise the regional nodes for tumors of the right renal pelvis or the right upper two-thirds of the ureter. A prospective study showed that an anatomical templatebased lymphadenectomy significantly improved patient survival in tumors of the renal pelvis. This benefit was more evident for patients with p T2 stage tumors or higher. The risk of regional node recurrence is significant reduced by template-based lymphadenectomy,which is likely to be associated with improved patient survival. The removal of lymph node micrometastases is assumed to be the reason for therapeutic benefit following lymphadenectomy. The number of resected lymph nodes can be used to assess the quality of lymphadenectomy,but not to determine the extent of lymphadenectomy. The guidelines currently recommend lymphadenectomy for patients with muscle-invasive disease,even though the current recommendation grades are still low. The present limitation of lymphadenectomy is the lack of standardization of the extent of lymphadenectomy and the randomized trials. Further studies are warranted to collect the evidence to support lymphadenectomy.

谷胱甘肽联合西地那非治疗勃起功能障碍患者临床疗效及对血管内皮功能的影响

目的探究谷胱甘肽联合西地那非治疗勃起功能障碍(ED)患者临床疗效及对血管内皮功能、炎性因子、勃起功能的影响。方法选取2022年10月—2023年10月新疆维吾尔自治区人民医院泌尿中心诊治ED患者89例作为研究对象,随机数字表法分为单药组44例和联合组45例。单药组给予西地那非口服治疗,联合组在单药组基础上给予还原型谷胱甘肽片口服治疗,2组患者均连续治疗1个月。观察2组患者治疗前、治疗结束时及治疗后1个月的血管内皮功能(NO、ET、VEGF、ES)、炎性因子(hs-CRP、IL-6、IL-8、IL-10)、勃起功能(IIEF-5、QEQ、EHS、PSV)变化,比较2组临床疗效、不良事件发生率。结果治疗结束后1个月,联合组临床治疗总有效率为91.11%,高于单药组的75.00%(χ^(2)/P=4.121/0.042);治疗结束时及治疗结束后1个月,联合组患者血清NO、VEGF水平显著高于单药组,ET水平显著低于单药组(治疗结束时:t/P=5.323/<0.001,3.808/<0.001,3.683/<0.001;治疗结束后1个月:t/P=2.615/0.011,3.197/0.002,3.089/0.003);血清hs-CRP、IL-6水平显著低于单药组(治疗结束时:t/P=8.323/<0.001,2.364/0.020;治疗结束后1个月:t/P=6.787/<0.001,2.662/0.009);IIEF-5、QEQ、EHS及PSV均显著高于治疗前,其中EHS及PSV也显著高于单药组(治疗结束时:t/P=6.410/<0.001,4.066/<0.001;治疗结束后1个月:t/P=8.928/<0.001,4.532/<0.001);2组患者不良事件发生率比较差异无统计学意义(P>0.05)。结论谷胱甘肽联合西地那非能够有效改善ED患者血管内皮功能及勃起功能,同时显著降低患者炎性因子水平,且对于ED患者具有显著临床疗效及安全性。

Controversies regarding transplantation of mesenchymal stem cells

Mesenchymal stem cells(MSCs)have tantalized regenerative medicine with their therapeutic potential,yet a cloud of controversies looms over their clinical tran-splantation.This comprehensive review navigates the intricate landscape of MSC controversies,drawing upon 15 years of clinical experience and research.We delve into the fundamental properties of MSCs,exploring their unique immuno-modulatory capabilities and surface markers.The heart of our inquiry lies in the controversial applications of MSC transplantation,including the perennial debate between autologous and allogeneic sources,concerns about efficacy,and lingering safety apprehensions.Moreover,we unravel the enigmatic mechanisms surro-unding MSC transplantation,such as homing,integration,and the delicate balance between differentiation and paracrine effects.We also assess the current status of clinical trials and the ever-evolving regulatory landscape.As we peer into the future,we examine emerging trends,envisioning personalized medicine and innovative delivery methods.Our review provides a balanced and informed perspective on the controversies,offering readers a clear understanding of the complexities,challenges,and potential solutions in MSC transplantation.

Clinacanthus nutans:a review of the medicinal uses,pharmacology and phytochemistry

Clinacanthus nutans Lindau is known as snake grass belonging to the Acanlhaceae family.This plant has diverse and potential medicinal uses in traditional herbal medicine for treating skin rashes,insects and snake bites,lesions caused by herpes simplex virus,diabetes,and gout in Malaysia.Indonesia.Thailand and China.Phylochemieal investigations documented the varied contents of bioaclive compounds from litis plant namely flavonoids,glycosides,glycoglyeerolipids.cerebrosides and monoacylmonogalatosylglycerol.The pharmacological experiment proved that various types of extracts and pure compounds from this species exhibited a broad range of biological properties such as anti-inflammatory,antiviral,antioxidant,and anti-diabetic activities.The lindings of toxicity study showed that extracts from this plant did not show any toxicity thus it can be used as strong therapeutic agents for specific diseased conditions.However,further experiments on chemical components and their mode of action showing biological activities are required to elucidate the complete phytochemical profile and assess to confirm their suitability tor future drugs.This review summarizes the medicinal uses,phytochemistry and pharmacology of this plant in order to explore its therapeutic potential and gaps necessitating for prospected research work.

Quranic Verse No. 8 of Surat Al-Jumu’ah Leads us to Describe Cancer and Determine Its True Cause (Part-III)

Therapeutic strategies for destroying cancer cells by making its death programs run again. The normal cell passes through several stages (Accumulation stage, Detoxification stage, Formation of free radical stage and Activation of nuclear factor kappa B stage and the shutting down of programs of cell death stage) to become a cancerous cell. The success of the therapeutic strategy to treat cancer depends on making either one or both programs of cell death run again. Shutting down one stage completely will be sufficient to stop the transformation of the natural cell into a cancerous cell, which eliminates the production of hydrogen peroxide, thus the activity of the NF-Kb will be inhibited. However, shutting down all stages is the most comprehensive therapeutic strategy and guarantees treatment success.

High-intensity focused ultrasound extracorporeal ablation of liver tissuesin rabbits

ＨｉｇｈｉｎｔｅｎｓｉｔｙｆｏｃｕｓｅｄｕｌｔｒａｓｏｕｎｄｅｘｔｒａｃｏｒｐｏｒｅａｌａｂｌａｔｉｏｎｏｆｌｉｖｅｒｔｉｓｓｕｅｓｉｎｒａｂｂｉｔｓＣＨＥＮＧＳｈｕＱｕｎ１，ＺＨＯＵＸｉｎＤａ１，ＴＡＮＧＺｈａｏＹｏｕ１，ＹＵＹａｏ１，Ｂ...

还原型谷胱甘肽联合苯巴比妥治疗新生儿黄疸的疗效分析

目的 分析还原型谷胱甘肽联合苯巴比妥治疗新生儿黄疸的效果。方法 选取2015年4月-2019年12月联勤保障部队第904医院收治的84例黄疸新生儿,以随机数字表法分为研究组和对照组,每组42例。两组均给予常规光疗,对照组在常规治疗基础上给予苯巴比妥,研究组在对照组基础上再给予还原型谷胱甘肽,两组均持续治疗7 d评价效果。对比两组光疗时间、皮肤退黄时间、肝功能、临床疗效、外周血细胞因子、免疫功能及治疗期间药物不良反应。结果 研究组光疗时间、皮肤退黄时间均低于对照组(P <0.05)。研究组治疗前后丙氨酸氨基转移酶、天门冬氨酸氨基转移酶、总胆红素、转铁蛋白、总胆汁酸、CD4^(+)/CD8^(+)的差值均高于对照组(P <0.05)。研究组总有效率高于对照组(P <0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 还原型谷胱甘肽联合苯巴比妥治疗新生儿黄疸可增强疗效,缩短光疗时间,促进黄疸消退,改善肝功能、TRF、TBA及免疫应答功能,且安全性良好。

The role of drug utilization evaluation in medical sciences

Background:Drug utilization evaluation(DUE)is defined by the World Health Organization(WHO)and focuses on the medical,social,and economic consequences of pharmaceutical marketing,distribution,prescribing,and usage in society.The WHO recommends a physician to every 1000 people.According to the recent data from the Health Ministry in 2019,in which 1.16 million doctors are of active population with just 80%,or 0.9 million,practicing.As a result,a ratio of 0.68 doctors for every 1000 people,which is much below as per the WHO reports.This article describes history,types,WHO guidelines,need and purpose of DUE.Objective:The main aim of this paper is to provide information about the rational use of medication in outpa­tient and inpatient department with special emphasis of DUEs.It also provides awareness directly to healthcare professionals,researchers,academicians,pharmacist and nurses to reduce the irrationality of medicines.Methods:The method used to compile this review information gathered from websites,Google scholar,PubMed,Research gate,and studies published on DUE from July 20 to Oct 22 were included as source of information.Results:We studied more than 35 published study on DUE,that reveals most of the physicians prescribed branded drugs not generic drugs,but WHO prescribing indicator allows to prescribe generic drugs in the hospital pharmacy to maintain better inventory control.It may also help to prevent pharmacist misunderstanding during dispensing.Conclusion:The use of generic prescription names avoids the possibility of medication product duplication and lowers patient costs.It is important to remember that incorrect medication prescriptions have impact on both patients and their family members.WHO indicators identify irrational prescribing behaviours to make therapy more rational and cost-effective.

甘草酸单铵半胱氨酸联合谷胱甘肽治疗抗结核药性肝损伤的疗效观察

目的:观察甘草酸单铵半胱氨酸联合谷胱甘肽(Glutathione,GSH)治疗抗结核药物性肝损伤(Anti-tuberculosis drug-induced liver injury,ATB-DILI)的疗效。方法:选取2020年3月至2022年3月间本院接收的80例由抗结核药引起药性肝损伤患者,根据信封随机法分为对照组和联合组,每组40例。对照组给予GSH治疗,联合组在前者基础上给予甘草酸单铵半胱氨酸治疗。比较两组患者的临床疗效、肝功能指标和血清炎性指标,统计不良反应发生率。结果:治疗后联合组总有效率明显高于对照组(P<0.05)。治疗后两组患者血清谷丙转氨酶(Glutamic pyruvic transaminase,ALT)、谷草转氨酶(Glutamic oxaloacetic transaminase,AST)、碱性磷酸酶(Alkaline phosphatase,ALP)、总胆红素(Total bilirubin,TBIL)、谷氨酰转移酶(Glutamyl transpeptidase,GGT)指标均下降,且联合组水平远低于对照组(P<0.05)。治疗后,两组患者白细胞介素-6(Interleukin-6,IL-6)和肿瘤坏死因子-α(Tumor necrosis factor,TNF-α)水平下降,且联合组水平低于对照组(P<0.05)。治疗期间联合组与对照组的不良反应总发生率比较无明显差异(P>0.05)。结论:甘草酸单铵半胱氨酸联合GSH治疗ATB-DILI疗效确切,有效改善肝功能指标和血清指标,并且没有不良反应的风险。

USE OF CELL-BASED BIOASSAY FOR THE QUALITY CONTROL OF BOTANICAL THERAPEUTICS

The single most important factor in modernization efforts of traditional oriental medicines is the limited understanding of active compounds responsible for claimed therapeutic effects.Indeed,the unknown identity of biologically active molecules generates major difficulties associated with botanical therapeutics in general.This includes management of raw materials,poor understanding of

DSG-Ⅲ型生物信息红外肝病治疗仪治疗慢性肝病31例疗效观察

目的:评估DSG-Ⅲ型生物信息红外肝病治疗仪(BILT肝病治疗仪)治疗慢性肝病的临床疗效。方法:选择慢性肝病60例,随机分为治疗组和对照组。对照组(n=29)以药物常规治疗,治疗组(n=31)在常规治疗的基础上加用BILT肝病治疗仪照射肝区(治疗时间为30 min,2次/d),在治疗前及治疗2周后,观察两组临床症状(乏力、纳差、腹胀、肝区不适)及肝功能指标(包括ALT、AST、DBIL、IBIL、γ-GT、ALP、ALB、GLB)的变化。结果:与治疗前比较,治疗组肝功能ALT、AST、DBIL、IBIL、ALP、γ-GT均显著降低(P<0.05),但ALB、GLB变化无统计学差异。而对照组中ALT、AST、DBIL、IBIL亦下降明显,但γ-GT、ALP、ALB、GLB变化无统计学差异。治疗后两组ALT比较有统计学差异[(42±28)IU/L与(86±71)IU/L(P<0.01)],治疗组ALT较对照组恢复更加明显。从临床症状,如乏力、纳差、肝区不适等来看,治疗组改善的例数和比率均优于对照组,差异有统计学意义(P<0.05)。而腹胀缓解方面,两组差异无统计学意义(P>0.05)。结论:BILT肝病治疗仪配合药物较单纯药物治疗慢性肝病可提高疗效,缓解患者部分临床症状。

复方甘草酸苷对慢性乙型肝炎肝纤维化的治疗作用

目的观察复方甘草酸苷对慢性乙型肝炎患者肝功能和肝纤维化的作用。方法将65例患者随机分为2组。治疗组35例给予复方甘草酸苷联合钾镁极化液治疗,对照组30例给予还原型谷胱甘肽联合钾镁极化液治疗,用药8周后观察临床症状、体征、肝功能及肝纤维化指标的变化。结果治疗组在各项指标的改善方面均较对照组有显著性差异(P<0.05),治疗组和对照组临床疗效分别为88.57%和73.33%(P<0.05),均未发现明显不良反应。结论复方甘草酸苷联合钾镁极化液对慢性乙型肝炎的临床疗效和延缓肝纤维化的作用均明显优于还原型谷胱甘肽联合钾镁极化液。

巴戟素对急性缺血性脑损伤保护作用的机制研究

巴戟素是从中药巴戟天中提取的一种糖甙类单体物。本实验采用生化检测和放射性核素示踪法 ,探讨巴戟素对缺血 /缺氧性脑损伤保护作用的机制。结果显示 :巴戟素可提高急性脑缺血衰老大鼠脑组织超氧化物歧化酶 (SOD)和谷胱甘肽过氧化酶 (GSH -Px)活性 (P <0 .0 1) ,减少过氧化脂质 (LPO)含量 (P<0 .0 5) ;能增加老龄小鼠脑组织葡萄糖含量 (P <0 .0 1) ;但对急性脑缺血衰老大鼠脑组织一氧化氮 (NO)含量无明显影响 (P >0 .0 5)。提示巴戟素对缺血性脑损伤保护作用的机制与抗脑组织的脂质过氧化作用及改善脑组织葡萄糖代谢有关。

黄芪对酒精性肝损伤小鼠MDA、GSH和TG的影响及肝脏保护作用的研究

目的:探讨黄芪总提取物(AM)对酒精性肝损伤小鼠丙二醛(MDA)、还原型谷胱甘肽(GSH)和甘油三酯(TG)的影响及其对肝脏保护作用。方法:将50只雄性昆明种小鼠随机分为5组:空白对照组、模型对照组和黄芪总提取物低、中、高剂量组,分别给药30d后,按试剂盒说明测定MDA含量、GSH活力和TG,进行肝脏病理组织学检查。结果:中、高剂量组能显著降低肝匀浆MDA含量和提高GSH含量;高剂量组能显著降低TG含量和改善肝脏脂变程度,与模型对照组比较,差异均具有统计学意义。结论:AM具有降低小鼠MDA和TG含量,提高GSH含量,对其肝脏具有保护作用。

还原型谷胱甘肽联合前列腺素E_1治疗慢性乙肝效果观察

目的 探讨治疗慢性乙型肝炎 (CHB)及抗肝纤维化的有效方法。方法 采用还原型谷胱甘肽 (GSH)联合前列腺素E1(PGE1)静脉滴注治疗CHB患者 112例 (治疗组 ) ,并与单用PGE1治疗 98例 (对照组 )进行比较 ,观察两组治疗前后血清Ⅲ型前胶原 (PCⅢ )、透明质酸 (HA)、层粘连蛋白 (LN)、Ⅳ型胶原 (Ⅳ -C)及肝功能 (ALT、AST、TBil)等指标变化情况。结果 治疗组临床疗效及肝功能改善明显优于对照组 (P均 <0 .0 1) ,而血清肝纤维化指标变化两组比较差异无显著性 (P >0 .0 5 )。结论 GSH和PGE1联合治疗CHB有较好的疗效 ,PGE1具有较好的抗肝纤维化作用 ,而GSH对肝纤维化的作用不突出。